OncoSec Medical Incorporated (ONCS) News

OncoSec Medical Incorporated (ONCS): $0.75

0.01 (+0.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ONCS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 486

in industry

Filter ONCS News Items

ONCS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ONCS News From Around the Web

Below are the latest news stories about ONCOSEC MEDICAL Inc that investors may wish to consider to help them evaluate ONCS as an investment opportunity.

OncoSec appoints new finance chief

OncoSec Medical Incorporated (ONCS) has appointed George Chi as Chief Financial Officer. Mr

Seeking Alpha | February 23, 2022

OncoSec Announces Appointment of George Chi as Chief Financial Officer

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced the appointment of George Chi as Chief Financial Officer.

Yahoo | February 22, 2022

OncoSec Announces Changes to its Board of Directors

PENNINGTON, N.J. and SAN DIEGO , Dec. 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS ) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body''s immune system to target and attack cancer, today announced that Margaret Dalesandro , Ph.D., Chair of the Board of Directors and member of the Leadership Committee, has resigned from the Board of Directors and the Leadership Committee, effective immediately, and Dr. Linda Shi , M.D., Ph.D., has been added to the OncoSec Board of Directors and appointed Chair. Kevin Smith remarked, "On behalf of the Board of Directors, we are grateful to Margaret for her leadership, expert guidance, and commitment to the company, particularl...

Benzinga | December 17, 2021

OncoSec Medical (NASDAQ:ONCS) Releases Quarterly Earnings Results

OncoSec Medical (NASDAQ:ONCS) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.25) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.37) by $0.12, Fidelity Earnings reports. Shares of ONCS traded up $0.01 during mid-day trading on Thursday, hitting $1.23. 4,172 shares of the company traded hands, compared to its []

Dakota Financial News | December 16, 2021

OncoSec Medical (NASDAQ:ONCS) Announces Earnings Results

OncoSec Medical (NASDAQ:ONCS) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.12, Fidelity Earnings reports. ONCS traded up $0.02 on Thursday, hitting $1.24. The company had a trading volume of 3,923 shares, compared to its average volume of 625,943. The […]

Dakota Financial News | December 16, 2021

State Street Corp Invests $56,000 in OncoSec Medical Incorporated (NASDAQ:ONCS)

State Street Corp purchased a new stake in shares of OncoSec Medical Incorporated (NASDAQ:ONCS) in the second quarter, HoldingsChannel reports. The institutional investor purchased 19,929 shares of the biotechnology companys stock, valued at approximately $56,000. Several other large investors also recently made changes to their positions in the company. Millennium Management LLC lifted its holdings []

Dakota Financial News | December 13, 2021

Analyzing Regulus Therapeutics (NASDAQ:RGLS) & OncoSec Medical (NASDAQ:ONCS)

Regulus Therapeutics (NASDAQ:RGLS) and OncoSec Medical (NASDAQ:ONCS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Insider & Institutional Ownership 26.3% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, []

Transcript Daily | December 1, 2021

Geode Capital Management LLC Increases Position in OncoSec Medical Incorporated (NASDAQ:ONCS)

Geode Capital Management LLC lifted its position in shares of OncoSec Medical Incorporated (NASDAQ:ONCS) by 29.7% during the second quarter, HoldingsChannel reports. The fund owned 183,322 shares of the biotechnology companys stock after acquiring an additional 41,987 shares during the quarter. Geode Capital Management LLCs holdings in OncoSec Medical were worth $515,000 as of its [] The post Geode Capital Management LLC Increases Position in OncoSec Medical Incorporated (NASDAQ:ONCS) appeared first on ETF Daily News .

ETF Daily News | November 27, 2021

Virtu Financial LLC Invests $36,000 in OncoSec Medical Incorporated (NASDAQ:ONCS)

Virtu Financial LLC acquired a new position in shares of OncoSec Medical Incorporated (NASDAQ:ONCS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 12,649 shares of the biotechnology company’s stock, valued at approximately $36,000. Several other large investors have also […]

Transcript Daily | November 27, 2021

OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

OncoSec Medical Incorporated (NASDAQ: ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET featuring key opinion leaders (KOLs) Matteo Carlino, MD, from Westmead and Blacktown Hospitals, Adil Daud, MD, from University of California San Francisco, Pablo Fernandez Peñas MD, PhD, FACD, from The University of Sydney, and Montaser Shaheen, MD, from the University of Arizona Cancer Center. The KOLs will discuss the clinical relevance of the upda

Yahoo | November 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.598 seconds.